Development and potential application of an oral ColoPulse infliximab tablet with colon specific release: A feasibility study

Maurer, J. M., Hofman, S., Schellekens, R. C. A., Tonnis, W. F., Dubois, A. O. T., Woerdenbag, H. J., Hinrichs, W. L. J., Kosterink, J. G. W. & Frijlink, H. W. 30-May-2016 In : International Journal of Pharmaceutics. 505, 1-2, p. 175-186 12 p.

Research output: Scientific - peer-reviewArticle

The monoclonal antibody infliximab is one of the cornerstones in the treatment of Crohn's disease. Local delivery of infliximab would be an alternative to overcome the inherent disadvantages of intravenous therapy. For this purpose 5 mg infliximab tablets were developed. To stabilize the antibody during production and storage it was incorporated in a sugar glass containing the oligosaccharide inulin. To obtain colon-specific release a ColoPulse coating was applied. The tablets were stored for 16 months under different conditions based on ICH climatic zone I: (C) 2016 Elsevier B.V. All rights reserved.

Original languageEnglish
Pages (from-to)175-186
Number of pages12
JournalInternational Journal of Pharmaceutics
Issue number1-2
StatePublished - 30-May-2016


  • Infliximab, Colon specific delivery, Oral delivery, ColoPulse, Crohn's disease, Protein stability, Formulation, CROHNS-DISEASE, LOCAL INJECTION, STABILITY, PROTEINS, BIOAVAILABILITY, STABILIZATION, ANTIBODIES, BEHAVIOR, GLASSES, INULIN

View graph of relations

ID: 33279388